AXS Investments LLC Sells 964 Shares of Pfizer Inc. (NYSE:PFE)

AXS Investments LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.8% during the first quarter, Holdings Channel.com reports. The fund owned 51,620 shares of the biopharmaceutical company’s stock after selling 964 shares during the period. AXS Investments LLC’s holdings in Pfizer were worth $1,308,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Pfizer by 7.7% in the fourth quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company’s stock worth $1,548,889,000 after purchasing an additional 4,167,222 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Pfizer by 3.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company’s stock worth $1,045,351,000 after purchasing an additional 1,333,740 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after purchasing an additional 9,041,990 shares during the last quarter. Finally, Pacer Advisors Inc. increased its holdings in shares of Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after purchasing an additional 17,957,928 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 3.2%

Shares of NYSE:PFE opened at $23.95 on Thursday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The business has a 50 day simple moving average of $24.40 and a two-hundred day simple moving average of $24.53. The firm has a market capitalization of $136.15 billion, a PE ratio of 12.74, a price-to-earnings-growth ratio of 0.90 and a beta of 0.52. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.33% and a net margin of 16.84%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.60 earnings per share. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. Pfizer’s payout ratio is presently 124.64%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Berenberg Bank reduced their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Thursday, May 29th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. Wolfe Research upped their price objective on Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research report on Wednesday, April 30th. Redburn Atlantic lowered their price objective on Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a research note on Wednesday, April 30th. Finally, Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $28.44.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.